Happy to share our most recent, open-access publication ”Cost-Effectiveness of Bivalent Respiratory Syncytial Virus Prefusion F Vaccine for Prevention of Respiratory Syncytial Virus Among Older Adults in Greece ” in Vaccines (Impact Factor:5.2).

Given the significant disease burden associated with Respiratory Syncytial Virus (RSV), particularly among older adults, there is a clear need for effective prevention strategies. Our study indicated that the availability of RSV vaccination could prevent over 74,000 medically attended cases and 1,706 deaths over the lifetime horizon of a cohort of adults aged 60 years and older. The effectiveness benefits associated with RSV vaccination translate to the accrual of more quality-adjusted life years (QALYs) compared with a no-vaccination strategy. Therefore, RSV vaccination is estimated to be a cost-effective strategy for preventing RSV disease in Greek adults aged over 60 years.

Find more at: Vaccines